BIS Stock Overview
ProShares Trust - ProShares UltraShort Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ProShares Trust - ProShares UltraShort Nasdaq Biotechnology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.09 |
| 52 Week High | US$26.51 |
| 52 Week Low | US$16.37 |
| Beta | 0 |
| 1 Month Change | 11.98% |
| 3 Month Change | 13.44% |
| 1 Year Change | -0.30% |
| 3 Year Change | -2.48% |
| 5 Year Change | -72.98% |
| Change since IPO | -99.59% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| BIS | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | -2.3% | 2.6% | 1.2% |
| 1Y | -0.3% | 31.6% | 24.9% |
Return vs Industry: BIS underperformed the US Capital Markets industry which returned 31.9% over the past year.
Return vs Market: BIS underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| BIS volatility | |
|---|---|
| BIS Average Weekly Movement | 4.9% |
| Capital Markets Industry Average Movement | 3.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIS has not had significant price volatility in the past 3 months.
Volatility Over Time: BIS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.proshares.com/our-etfs/leveraged-and-inverse/bis |
ProShares Trust - ProShares UltraShort Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. It invests through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors.
ProShares Trust - ProShares UltraShort Nasdaq Biotechnology Fundamentals Summary
| BIS fundamental statistics | |
|---|---|
| Market cap | US$3.41m |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BIS perform over the long term?
See historical performance and comparison